
|Videos|December 8, 2021
Current challenges in the treatment of high-risk non-metastatic RCC
Author(s)Urology Times staff
“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.
Advertisement
In this video, Pavlos Msaouel, MD, PhD, discusses challenges that physicians face when treating patient with high-risk non-metastatic renal cell carcinoma, which were highlighted in his presentation, “The future of adjuvant therapy for high-risk non-metastatic RCC,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Msaouel is an assistant professor in the department of genitourinary medical oncology of the division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











